Search Results - "Bardet, V"

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes by Mathis, S, Chapuis, N, Debord, C, Rouquette, A, Radford-Weiss, I, Park, S, Dreyfus, F, Lacombe, C, Béné, M C, Kosmider, O, Fontenay, M, Bardet, V

“…Several groups have published flow cytometry scores useful for the diagnosis or prognosis of myelodysplastic syndromes (MDS), mainly based on the detection of…”
Get full text

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies by Chapuis, N, Tamburini, J, Green, A S, Willems, L, Bardet, V, Park, S, Lacombe, C, Mayeux, P, Bouscary, D

“…Mammalian target of rapamycin (mTOR) is a protein kinase implicated in the regulation of various cellular processes, including those required for tumor…”
Get full text

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML by Park, S, Chapuis, N, Bardet, V, Tamburini, J, Gallay, N, Willems, L, Knight, Z A, Shokat, K M, Azar, N, Viguié, F, Ifrah, N, Dreyfus, F, Mayeux, P, Lacombe, C, Bouscary, D

“…The phosphatidylinositol 3-kinase (PI3K)/Akt and mammalian target of rapamycin complex 1 (mTORC1) signaling pathways are frequently activated in acute…”
Get full text

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia by PARK, Sophie, CHAPUIS, Nicolas, TAMBURINI, Jérôme, BARDET, Valérie, CORNILLET-LEFEBVRE, Pascale, WILLEMS, Lise, GREEN, Alexa, MAYEUX, Patrick, LACOMBE, Catherine, BOUSCARY, Didier

“…The PI3K/AKT and mTOR signaling pathways are activated in acute myeloid leukemia, including in the more immature leukemic populations. Constitutive PI3K…”
Get full text

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent by Angelot-Delettre, Fanny, Roggy, Anne, Frankel, Arthur E, Lamarthee, Baptiste, Seilles, Estelle, Biichle, Sabeha, Royer, Bernard, Deconinck, Eric, Rowinsky, Eric K, Brooks, Christopher, Bardet, Valerie, Benet, Blandine, Bennani, Hind, Benseddik, Zehaira, Debliquis, Agathe, Lusina, Daniel, Roussel, Mikael, Solly, Françoise, Ticchioni, Michel, Saas, Philippe, Garnache-Ottou, Francine

“…Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of…”
Get full text

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML by Ettou, S, Audureau, E, Humbrecht, C, Benet, B, Jammes, H, Clozel, T, Bardet, V, Lacombe, C, Dreyfus, F, Mayeux, P, Solary, E, Fontenay, M

“…absent…”
Get full text

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody by CHAPUIS, Nicolas, TAMBURINI, Jérôme, MAYEUX, Patrick, LACOMBE, Catherine, BOUSCARY, Didier, CORNILLET-LEFEBVRE, Pascale, GILLOT, Lucile, BARDET, Valérie, WILLEMS, Lise, PARK, Sophie, GREEN, Alexa S, IFRAH, Norbert, DREYFUS, François

“…Alterations in the PI3K/Akt pathway are found in a wide range of cancers and the development of PI3K inhibitors represents a promising approach to cancer…”
Get full text

Schistocytes in disseminated intravascular coagulation by Lesesve, J.-F., Martin, M., Banasiak, C., André-Kerneïs, E., Bardet, V., Lusina, D., Kharbach, A., Geneviève, F., Lecompte, T.

“…Summary Introduction The presence of schistocytes on the peripheral blood film during disseminated intravascular coagulation (DIC) remains controversial…”
Get full text

Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide by Park, S, Vassilieff, D, Bardet, V, Viguié, F, Dreyfus, F

Get full text

104 APG101 (SOLUBLE CD95-FC) IMPROVES BFU-E GROWTH IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH COLLAPSED ERYTHROPOIESIS: A PRECLINICAL STUDY by Raimbault, A, Bondu, S, Pierre-Eugene, C, Deudon, C, Willems, L, Frisan, E, Chapuis, N, Sapena, R, Rouquette, A, Kunz, C, Fricke, H, Kosmider, O, Bardet, V, Fontenay, M

Get full text

P-071 Flow cytometric detection of dyserythropoiesis is a sensitive and powerful tool for myelodysplastic syndrome diagnosis by Mathis, S, Chapuis, N, Debord, C, Radford-Weiss, I, Park, S, Dreyfus, F, Kosmider, O, Fontenay, M, Bardet, V

Get full text

Diagnostic and therapeutic considerations on inherited platelet disorders in neonates and children by Schlegel, N, Bardet, V, Kenet, G, Muntean, W, Zieger, B, Nowak-Göttl, U

“…Inherited disorders of platelets constitute a group of rare diseases that give rise to bleeding syndromes of variety severity, with more severe cases being…”
Get more information

Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutations by Cornillet-Lefebvre, P, Cuccuini, W, Bardet, V, Tamburini, J, Gillot, L, Ifrah, N, Nguyen, P, Dreyfus, F, Mayeux, P, Lacombe, C, Bouscary, D

Get full text

Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype by Bardet, V, Costa, L D, Elie, C, Malinge, S, Demur, C, Tamburini, J, Lefebvre, P C, Witz, F, Lioure, B, Jourdan, E, Pigneux, A, Ifrah, N, Attal, M, Dreyfus, F, Mayeux, P, Lacombe, C, Bennaceur-Griscelli, A, Bernard, O A, Bouscary, D, Récher, C

Get full text

C034 Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS by Pawlikowska, P, Kosmider, O, Park, S, Bardet, V, Kuhnowsky, F, Pierre-Eugene, C, Picard, F, Viallon, V, Viguie, F, Mayeux, P, Lacombe, C, Porteu, F, Dreyfus, F, Fontenay, M

Get full text

The MYH9 syndrome: report of a new case with a new mutation of the MYH9 gene by Schleinitz, N, Favier, R, Mazodier, K, Difeo, A, Ebbo, M, Veit, V, Berda-Haddad, Y, Bernit, E, Heudier, P, Kaplanski, G, Camoin, L, Bardet, V, Harle, J-R

“…Familial macrothrombocytopenias are a group of rare autosomal dominant platelet disorders including many syndromes in particular the May-Hegglin anomaly. They…”
Get full text

P-80 Improved predictive factors ofresponse for myelodysplastic syndrome patients treated by the combination of erythropoietin and G-CSF by Park, S., Kelaidi, C., Grabar, S., Bardet, V., Vassilieff, D., Picard, F., Guesnu, M., Quarre, M.-C., Fenaux, P., Dreyfus, F.

Get full text

Mapping of chromosome 20 for loss of heterozygosity in childhood ALL reveals a 1000-kb deletion in one patient by COUQUE, N, CHAMBON-PAUTAS, C, CAVE, H, BARDET, V, DUVAL, M, VILMER, E, GRANDCHAMP, B

“…The long arm of chromosome 20 displays recurrent loss of heterozygosity (LOH) for microsatellite markers in blast cells from children with acute lymphoblastic…”
Get full text

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms by Bardet, Valérie, Wagner-Ballon, Orianne, Guy, Julien, Morvan, Céline, Debord, Camille, Trimoreau, Franck, Benayoun, Emmanuel, Chapuis, Nicolas, Freynet, Nicolas, Rossi, Cédric, Mathis, Stéphanie, Gourin, Marie-Pierre, Toma, Andréa, Béné, Marie C, Feuillard, Jean, Guérin, Estelle

“…Although numerous recent publications have demonstrated interest in multiparameter flow cytometry in the investigation of myelodysplastic disorders, it is…”
Get full text

Le syndrome MYH9 : à propos d'une nouvelle observation et de la mise en évidence d'une nouvelle mutation du gène MYH9 by Schleinitz, N., Favier, R., Mazodier, K., Difeo, A., Ebbo, M., Veit, V., Berda-Haddad, Y., Bernit, E., Heudier, P., Kaplanski, G., Camoin, L., Bardet, V., Harle, J.-R.

“…Le groupe des thrombopénies constitutionnelles avec macroplaquettes associées à des inclusions leucocytaires comprend plusieurs syndromes dont le syndrome de…”
Get full text